Clinical Research Directory

Inclusion Criteria: 1. Age: 18-75 years; 2. Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; 3. Diagnosis: Histologically or pathologically confirmed gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction; 4. Prior Treatment: Disease progression or failure after receiving second-line or later chemotherapy; 5. TNM Stage: TNM Stage IV (TanyNanyM1); 6. Measurable Disease: Presence of at least one radiologically evaluable lesion per RECIST v1.1 criteria (or other applicable criteria) within 21 days prior to enrollment; 7. Adequate Organ Function: Defined as follows within specified timeframes before enrollment; * Hematology: * Absolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹/L * Platelet count (PLT) ≥ 90 × 10⁹/L * Hemoglobin (Hb) ≥ 90 g/L * Biochemistry: * Total Bilirubin (TBIL) ≤ Upper Limit of Normal (ULN) * Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 1.5 × ULN * Alkaline Phosphatase (ALP) ≤ 2.5 × ULN * Blood Urea Nitrogen (BUN) and Serum Creatinine (Cr) ≤ 1.5 × ULN * Creatinine Clearance (CrCl) ≥ 50 mL/min (calculated using the Cockcroft-Gault formula) * Coagulation: * International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 × ULN * Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN * Cardiac Function: * Left Ventricular Ejection Fraction (LVEF) ≥ 55% as measured by Echocardiography (ECHO) or Multigated Acquisition Scan (MUGA) * Corrected QT interval using Fridericia's formula (QTcF) \< 470 ms for females and \< 450 ms for males on Electrocardiogram (ECG); 8. Informed Consent: Voluntarily provide written informed consent prior to any study-specific procedures. Exclusion Criteria: 1. Prior TAS-102: Previous treatment with TAS-102; 2. Concurrent Anticancer Therapy: Concurrent participation in another clinical trial involving anticancer therapy; 3. Recent Major Surgery: Undergone major surgical procedures within 4 weeks prior to enrollment, or has not fully recovered from such procedures; 4. Significant Cardiac Disease: History or presence of clinically significant cardiac disease, including but not limited to: * History of congestive heart failure (CHF) or systolic dysfunction (LVEF \< 50%). * High-risk uncontrolled arrhythmias, significant ventricular arrhythmia (e.g., ventricular tachycardia), or high-grade atrioventricular block. * Angina pectoris requiring anti-anginal medication. * Clinically significant valvular heart disease. * ECG evidence of transmural myocardial infarction. * Poorly controlled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 100 mmHg); 5. General Exclusion: Any other condition that, in the judgment of the Investigator, would make the subject unsuitable for participation in the study or compromise protocol compliance.